Geldanamycin

Discontinued Product

1368 has been discontinued.

View all Hsp90 products.
Description: Selective Hsp90 inhibitor
Chemical Name: 9,13-Dihydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-2-azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9-carbamate
Purity: ≥98% (HPLC)
Datasheet
Citations (5)
Reviews (2)
Literature (2)

Biological Activity for Geldanamycin

Geldanamycin is a selectively inhibits heat shock protein 90 (Hsp90). Binds to the ATP site of Hsp90 (Kd = 1.2 μM) and inhibits its chaperone activity. Consequently inhibits activities of oncogenic kinases (e.g. src, Raf), p53 and steroid receptors. Demonstrates antiproliferative effect on breast cancer stem-like cells.

Technical Data for Geldanamycin

M. Wt 560.64
Formula C29H40N2O9
Storage Desiccate at -20°C
Purity ≥98% (HPLC)
CAS Number 30562-34-6
PubChem ID 13017912
InChI Key QTQAWLPCGQOSGP-PHLMVCJGSA-N
Smiles O=C1C(OC)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(C)/[C@H](OC(N)=O)[C@@H](OC)/C=C/C=C(C)/C2=O)C(C(N2)=C1)=O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Geldanamycin

Certificate of Analysis / Product Datasheet
Select another batch:

View Related Products by Product Action

View all Hsp90 Inhibitors

Keywords: Geldanamycin, Geldanamycin supplier, Selective, Hsp90, inhibitors, inhibits, Heat, Shock, Protein, 90, antibiotics, Antibiotics, Stem, Cell, Signaling, Cancer, Cells, 1368, Tocris Bioscience

5 Citations for Geldanamycin

Citations are publications that use Tocris products. Selected citations for Geldanamycin include:

Khalafalla et al (2017) P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy. J Biol Chem 292 16626 PMID: 28798231

Young et al (2015) A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90. BMC Dev Biol 11 113 PMID: 25700737

Chung-Davidson et al (2015) Hsp90 and hepatobiliary transformation during sea lamprey metamorphosis. Nucleic Acids Res 15 47 PMID: 26627605

Yang et al (2018) NudCL2 is an Hsp90 cochaperone to regulate sister chromatid cohesion by stabilizing cohesin subunits. Cell Mol Life Sci PMID: 30368549


Reviews for Geldanamycin

Average Rating: 5 (Based on 2 Reviews.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%

Have you used Geldanamycin?

Submit a review and receive an Amazon gift card.

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


Good Hsp90 blocker.
By Anonymous on 01/27/2023
Assay Type: In Vitro
Species: Rat
Cell Line/Tissue: Primary hippocampal neurons

The drug was incubated at 10 μM to inhibit Hsp90.


Geldanamycin was used in resistance experiments.
By Anonymous on 02/27/2019
Species: Human

Geldanamycin was used in resistance experiments. We investigated the Hsp90 family protein (HtpG) of the organism that makes GdA, S. hygroscopicus.

review image

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cell Cycle and DNA Damage Research Product Guide

Cell Cycle and DNA Damage Research Product Guide

This product guide provides a review of the cell cycle and DNA damage research area and lists over 150 products, including research tools for:

  • Cell Cycle and Mitosis
  • DNA Damage Repair
  • Targeted Protein Degradation
  • Ubiquitin Proteasome Pathway
  • Chemotherapy Targets
Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.